| You are here: Home: BCU 5|2002: George W Sledge, Jr, MD - Select Publications
Select Publications
Adjuvant trastuzumab and cardiac function
Carey LA. Cardiotoxicity of trastuzumab (Herceptin, H)
given with weekly Taxol (T) immediately following 4AC as initial
therapy for primary breast cancer (BrCa). Proc ASCO 2002;Abstract
253.
Ewer MS. Trastuzumab (Herceptin) cardiotoxicity: Clinical
course and cardiac biopsy correlations. Proc ASCO 2002;Abstract
489.
Gerber B et al. Effectiveness of trastuzumab (Herceptin)
in a patient with locally recurrent breast cancer after cardiac
failure caused by severe cytotoxic pretreatment. Oncology
2001;61:271-4. Abstract
Hortobagyi GN, Perez EA. Integration of trastuzumab into
adjuvant systemic therapy of breast cancer: Ongoing and planned
clinical trials. Semin Oncol 2001;28:41-6. Abstract
Leyland-Jones B. Trastuzumab: Hopes and realities. Lancet
Oncol 2002;3(3):137-44. Abstract
Leyland-Jones B, Smith I. Role of Herceptin in primary
breast cancer: Views from North America and Europe. Oncology
2001;61 Suppl 2:83-91. Abstract
Lueck H-JH-J. Cardiac safety of Herceptin (H) in combination
with epirubicin (E) plus cyclophosphamide (C): Interim results of
a phase II study in patients with metastatic breast cancer.
Breast Cancer Res Treat 2001;Abstract
439.
Nabholtz JM, Slamon D. New adjuvant strategies for breast
cancer: Meeting the challenge of integrating chemotherapy and trastuzumab
(Herceptin). Semin Oncol 2001;28:1-12. Abstract
Paik S, Park C. HER-2 and choice of adjuvant chemotherapy
in breast cancer. Semin Oncol 2001;28:332-5. Abstract
Perez EA. The role of adjuvant monoclonal antibody therapy
for breast cancer: Rationale and new studies. Curr Oncol
Rep 2001;3:516-22. Abstract
Rastogi F et al. Differences in cardiac ejection fractions
for breast cancer patients treated with doxorubicin or trastuzumab.
Proc ASCO 2002; Abstract
262.
Schneider JW et al. Cardiotoxicity in signal transduction
therapeutics: ErbB2 antibodies and the heart. Semin Oncol
2001;28(5 Suppl 16):18-26. Abstract
Seidman A et al. Cardiac dysfunction in the trastuzumab
clinical trials experience. J Clin Oncol 2002;20(5):1215-21.
Abstract
Slamon D, Pegram M. Rationale for trastuzumab (Herceptin)
in adjuvant breast cancer trials. Semin Oncol 2001;28:13-9.
Abstract
Sledge GW et al. Pilot trial of paclitaxel-Herceptin adjuvant
therapy for early stage breast cancer (E2198). Breast Cancer
Res Treat 2001;Abstract
4.
Sparano JA. Cardiac toxicity of trastuzumab (Herceptin):
Implications for the design of adjuvant trials. Semin Oncol
2001;28:20-7. Abstract
Tripathy D et al. Effect of cardiac dysfunction on treatment
outcome in the Herceptin (trastuzumab) pivotal trial. Breast
Cancer Res Treat 2001;Abstract
525.
|
